SGN-CD70A is a new antibody-drug conjugate (ADC) targeted to CD70 using the company’s new ADC technology. The open-label, multi-center, dose-escalation Phase I trial is designed to evaluate the
As part of the deal, Sigma-Tau will be responsible for the sales, marketing and distribution of Colief in the US. Sigma-Tau has planned a re-launch of Colief at
The company secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for the product, which is indicated as monotherapy,
Diprivan is an intravenous sedative-hypnotic agent for use in the induction and maintenance of anesthesia or sedation. Fresenius Kabi USA president and CEO John Ducker said the Diprivan
The NDS is based on results from two pivotal Phase III trials, REFINE-1 and REFINE-2, which were reported in late 2013. In these trials, the majority of ATX-101
The approval follows after a request from the Liberian Government on 8 August to send sample doses of experimental Serum for use on two Liberian doctors who are
The fresh round of charges was said to be seen by Reuters news agency in an anonymous email sent to chief executive Andrew Witty and GSK audit committee
Conducted on 15 healthy volunteers at Linear Clinical Research’s facility in Perth, Australia, the study validated additional pharmacokinetic parameters associated with the safety and elimination profile that remained
The retinal device will be offered to late-stage retinitis pigmentosa (RP) patients in six German university clinics and teaching hospitals. Retina Implant CEO Walter-G Wrobel said: "Since receiving
Sanofi and Mannkind have signed an exclusive licensing agreement to develop and market the latter’s inhaled insulin diabetes therapy Afrezza. Under the terms of the agreement, France-based Sanofi
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.